journal
MENU ▼
Read by QxMD icon Read
search

Prostate Cancer and Prostatic Diseases

journal
https://www.readbyqxmd.com/read/28220805/meta-analysis-of-metabolic-syndrome-and-prostate-cancer
#1
REVIEW
M Gacci, G I Russo, C De Nunzio, A Sebastianelli, M Salvi, L Vignozzi, A Tubaro, G Morgia, S Serni
BACKGROUND: Metabolic syndrome (MetS) and prostate cancer (PCa) are highly prevalent conditions worldwide. Current evidence suggests the emerging hypothesis that MetS could play a role in the development and progression of several neoplasms. The aims of this study are to evaluate the impact of MetS and MetS factors on PCa incidence, on the risk of high-grade PCa and to analyze the role of MetS and single MetS components on the development of aggressive PCa features. METHODS: A systematic literature search and analysis on PubMed, EMBASE, Cochrane and Academic One File databases until September 2015 was performed by 2 independent reviewers to evaluate the associations between MetS and PCa incidence, and between MetS and high-grade PCa incidence (bioptical Gleason Score⩾8, Prognostic Group 4-5 according to the novel prostate cancer grading system)...
February 21, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28220804/impact-of-symptomatic-skeletal-events-on-health-care-resource-utilization-and-quality-of-life-among-patients-with-castration-resistant-prostate-cancer-and-bone-metastases
#2
R McKay, B Haider, M S Duh, A Valderrama, M Nakabayashi, M Fiorillo, L Ristovska, L Wen, P Kantoff
BACKGROUND: Data regarding the impact of symptomatic skeletal events (SSEs) on health economics and patient-reported outcomes in men with castration-resistant prostate cancer (CRPC) and bone metastases from a clinical setting are lacking. Hence, this study aimed to quantify the effects of SSEs on health-care resource utilization (HRU), health-related quality of life (HRQoL) and pain in men with CRPC metastasized to bone. METHODS: This cohort study included men with CRPC and bone metastasis treated at a tertiary center during December 1996-July 2015...
February 21, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28220803/tcf7-is-suppressed-by-the-androgen-receptor-via-microrna-1-mediated-downregulation-and-is-involved-in-the-development-of-resistance-to-androgen-deprivation-in-prostate-cancer
#3
M K Siu, W-Y Chen, H-Y Tsai, H-Y Chen, J J Yin, C-L Chen, Y-C Tsai, Y-N Liu
BACKGROUND: Resistance to androgen deprivation therapy (ADT) represents a key step in the malignant progression of prostate cancer, and mutation to androgen receptor (AR) is one major driver to an androgen-independent phenotype. However, alternative oncogenic pathways that bypass AR signaling have emerged as an important mechanism promoting resistance to ADT. It is known that AR activation can prevent the interaction between β-catenin and T cell factor/lymphoid enhancer-binding factor (TCF/LEF) family, inhibiting the Wnt signaling pathway...
February 21, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28220802/the-prostate-cancer-prevention-trial-risk-calculator-2-0-performs-equally-for-standard-biopsy-and-mri-us-fusion-guided-biopsy
#4
M Maruf, M Fascelli, A K George, M M Siddiqui, M Kongnyuy, J M DiBianco, A Muthigi, S Valayil, A Sidana, T P Frye, A Kilchevsky, P L Choyke, B Turkbey, B J Wood, P A Pinto
BACKGROUND: The Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPTRC) is a widely used risk-based calculator used to assess a man's risk of prostate cancer (PCa) before biopsy. This risk calculator was created from data of a patient cohort undergoing a 6-core sextant biopsy, and subsequently validated in men undergoing 12-core systematic biopsy (SBx). The accuracy of the PCPTRC has not been studied in patients undergoing magnetic resonance imaging/ultrasound (MRI/US) fusion-guided biopsy (FBx)...
February 21, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28195223/celastrol-an-active-constituent-of-the-tcm-plant-tripterygium-wilfordii-hook-f-inhibits-prostate-cancer-bone-metastasis
#5
K Kuchta, Y Xiang, S Huang, Y Tang, X Peng, X Wang, Y Zhu, J Li, J Xu, Z Lin, T Pan
BACKGROUND: Treatment failure of prostate cancer (PCa) is often due to bone metastasis. Celastrol, an active constituent of Tripterygium wilfordii roots, has shown anti-tumor effects in previous studies in accordance with its indication in traditional Chinese medicine. METHODS: Using a PC-3 cell model, in vitro assays were performed to evaluate the effects of celastrol on proliferation, migration (wound healing assay), tissues invasion (Transwell-Matrigel penetration assay) and vascular endothelial growth factor (VEGF) secretion (enzyme-linked immunosorbent assay)...
February 14, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28139757/establishing-the-distribution-of-satellite-lesions-in-intermediate-and-high-risk-prostate-cancer-implications-for-focused-radiotherapy
#6
J V Hegde, D J Margolis, P-C Wang, R E Reiter, J Huang, M L Steinberg, M Kamrava
BACKGROUND: In focused radiotherapy for prostate cancer (PC), a full dose of radiation is delivered to the index lesion while reduced dose is delivered to the remaining prostate to reduce morbidity. As PC is commonly multifocal, we investigated whether baseline clinical characteristics or multiparametric magnetic resonance imaging (mpMRI) may be useful to predict the actual pathologic distribution of PC in men with intermediate- or high-risk PC, which may better inform how to deliver focused radiotherapy...
January 31, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28117387/use-of-the-prostate-health-index-for-detection-of-prostate-cancer-results-from-a-large-academic-practice
#7
J J Tosoian, S C Druskin, D Andreas, P Mullane, M Chappidi, S Joo, K Ghabili, J Agostino, K J Macura, H B Carter, E M Schaeffer, A W Partin, L J Sokoll, A E Ross
BACKGROUND: The Prostate Health Index (phi) outperforms PSA and other PSA derivatives for the diagnosis of prostate cancer (PCa). The impact of phi testing in the real-world clinical setting has not been previously assessed. METHODS: In a single, large, academic center, phi was tested in 345 patients presenting for diagnostic evaluation for PCa. Findings on prostate biopsy (including Grade Group (GG), defined as GG1: Gleason score (GS) 6, GG2: GS 3+4=7, GG3: GS 4+3=7, GG4: GS 8 and GG5: GS 9-10), magnetic resonance imaging (MRI) and radical prostatectomy (RP) were prospectively recorded...
January 24, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28117386/lifestyle-guidelines-for-managing-adverse-effects-on-bone-health-and-body-composition-in-men-treated-with-androgen-deprivation-therapy-for-prostate-cancer-an-update
#8
REVIEW
P J Owen, R M Daly, P M Livingston, S F Fraser
BACKGROUND: Men treated with androgen deprivation therapy (ADT) for prostate cancer are prone to multiple treatment-induced adverse effects, particularly with regard to a deterioration in bone health and altered body composition including decreased lean tissue mass and increased fat mass. These alterations may partially explain the marked increased risk in osteoporosis, falls, fracture and cardiometabolic risk that has been observed in this population. METHODS: A review was conducted that assessed standard clinical guidelines for the management of ADT-induced adverse effects on bone health and body composition in men with prostate cancer...
January 24, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28117385/radiographic-progression-with-nonrising-psa-in-metastatic-castration-resistant-prostate-cancer-post-hoc-analysis-of-prevail
#9
A H Bryce, J J Alumkal, A Armstrong, C S Higano, P Iversen, C N Sternberg, D Rathkopf, Y Loriot, J de Bono, B Tombal, S Abhyankar, P Lin, A Krivoshik, D Phung, T M Beer
BACKGROUND: Advanced prostate cancer is a phenotypically diverse disease that evolves through multiple clinical courses. PSA level is the most widely used parameter for disease monitoring, but it has well-recognized limitations. Unlike in clinical trials, in practice, clinicians may rely on PSA monitoring alone to determine disease status on therapy. This approach has not been adequately tested. METHODS: Chemotherapy-naive asymptomatic or mildly symptomatic men (n=872) with metastatic castration-resistant prostate cancer (mCRPC) who were treated with the androgen receptor inhibitor enzalutamide in the PREVAIL study were analyzed post hoc for rising versus nonrising PSA (empirically defined as >1...
January 24, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28117384/formalin-disinfection-of-prostate-biopsy-needles-may-reduce-post-biopsy-infectious-complications
#10
N Singla, J Walker, S L Woldu, N M Passoni, K de la Fuente, C G Roehrborn
BACKGROUND: We sought to determine whether formalin disinfection of prostate biopsy needles between cores reduces post-biopsy urinary tract infections (UTIs). METHODS: We reviewed a single-surgeon experience of transrectal prostate biopsies from 2010 to 2014. Biopsies were performed in either an operative suite, where 10% formalin was used to disinfect the needle tip between each biopsy core, or an outpatient clinic, where formalin was not used. Our primary outcome was post-biopsy UTI rates, defined as a positive urine culture within 30 days of biopsy...
January 24, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28117383/utilization-of-biopsy-based-genomic-classifier-to-predict-distant-metastasis-after-definitive-radiation-and-short-course-adt-for-intermediate-and-high-risk-prostate-cancer
#11
P L Nguyen, N E Martin, V Choeurng, B Palmer-Aronsten, T Kolisnik, C J Beard, P F Orio, M D Nezolosky, Y-W Chen, H Shin, E Davicioni, F Y Feng
BACKGROUND: We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT). METHODS: We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive radiation plus a median of 6 months of ADT (range 3-39 months) from 2001-2013 at a single center and had available biopsy tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement were macrodissected for RNA extraction...
January 24, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28117382/the-impact-of-comorbidity-and-psa-doubling-time-on-the-risk-of-death-in-men-experiencing-psa-failure-following-radiation-therapy-with-or-with-androgen-deprivation-therapy-for-unfavorable-risk-prostate-cancer
#12
S A Patel, M-H Chen, M Loffredo, A Renshaw, P W Kantoff, A V D'Amico
BACKGROUND: The optimal management of men with PSA failure following initial prostate cancer (PC) therapy stratified by comorbidity is unknown. We investigated the impact that PSA doubling time (DT) and comorbidity had on the risk of all-cause mortality (ACM), prostate cancer-specific mortality (PCSM) and other-cause mortality (OCM) following PSA failure. METHODS: Between 1995 and 2001, 206 men with unfavorable-risk PC were randomized to receive radiation therapy alone or in combination with 6 months of androgen deprivation therapy (ADT); 108 men experienced PSA failure and formed the study cohort...
January 24, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28094251/is-prostate-cancer-stage-migration-continuing-for-black-men-in-the-psa-era
#13
R W Dobbs, D T Greenwald, H Wadhwa, V L Freeman, M R Abern
BACKGROUND: In the United States, disease-specific mortality from prostate cancer (PC) is highest among black men. While the introduction of widespread PSA testing has been associated with a downward stage migration, whether this trend continues in the late PSA era and for black men is unknown. The objective of our study was to evaluate current PC stage migration patterns in the United States by race. METHODS: The Surveillance, Epidemiology and End Results (SEER) registry was queried to obtain all cases of PC reported between 2000 and 2013...
January 17, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28094250/end-of-radiation-psa-as-a-novel-prognostic-factor-in-patients-undergoing-definitive-radiation-and-androgen-deprivation-therapy-for-prostate-cancer
#14
A K Narang, J Trieu, N Radwan, A Ram, S P Robertson, P He, C Gergis, E Griffith, H Singh, T A DeWeese, S Honig, A Annadanam, S Greco, C DeVille, T McNutt, T L DeWeese, D Y Song, P T Tran
BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993 to 2006 and who had an end-of-radiation (EOR) PSA (n=688, median follow-up 11.2 years). We analyzed the association of an EOR PSA level, obtained during the last week of radiation, with survival outcomes...
January 17, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28071673/prognostic-value-of-the-new-grade-groups-in-prostate-cancer-a-multi-institutional-european-validation-study
#15
R Mathieu, M Moschini, B Beyer, K M Gust, T Seisen, A Briganti, P Karakiewicz, C Seitz, L Salomon, A de la Taille, M Rouprêt, M Graefen, S F Shariat
BACKGROUND: We aimed to assess the prognostic relevance of the new Grade Groups in Prostate Cancer (PCa) within a large cohort of European men treated with radical prostatectomy (RP). METHODS: Data from 27 122 patients treated with RP at seven European centers were analyzed. We investigated the prognostic performance of the new Grade Groups (based on Gleason score 3+3, 3+4, 4+3, 8 and 9-10) on biopsy and RP specimen, adjusted for established clinical and pathological characteristics...
January 10, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28071672/metformin-and-the-risk-of-prostate-cancer-across-racial-ethnic-groups-a-population-based-cohort-study
#16
C B Chen, D T Eurich, S R Majumdar, J A Johnson
BACKGROUND: Men with diabetes may have a lower risk of prostate cancer than men without diabetes which may be altered by metformin use or race/ethnicity. METHODS: Using administrative databases, from 1994 to 2012, adult (age⩾50 years) men with diabetes were identified. Metformin exposure was defined as a time-dependent variable, stratified first into any use, and into tertiles of cumulative dose. Surname algorithms identified individuals as Chinese or non-Chinese...
January 10, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28045115/skeletal-related-events-significantly-impact-health-related-quality-of-life-in-metastatic-castration-resistant-prostate-cancer-data-from-prevail-and-affirm-trials
#17
F Saad, C Ivanescu, D Phung, Y Loriot, S Abhyankar, T M Beer, B Tombal, S Holmstrom
BACKGROUND: We investigated the impact of skeletal-related events (SREs) on health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) in phase III trials of enzalutamide versus placebo. METHODS: Patients with mCRPC experiencing at least one SRE during AFFIRM and PREVAIL were assessed for trajectory-adjusted mean change in HRQoL by first SRE using Functional Assessment of Cancer Therapy-Prostate (FACT-P; AFFIRM, three domains, and PREVAIL, nine domains) and EQ-5D (PREVAIL) instruments...
January 3, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28045113/unscreened-older-men-diagnosed-with-prostate-cancer-are-at-increased-risk-of-aggressive-disease
#18
J J Tosoian, R Alam, C Gergis, A Narang, N Radwan, S Robertson, T McNutt, A E Ross, D Y Song, T L DeWeese, P T Tran, P C Walsh
BACKGROUND: To evaluate the relationship between PSA testing history and high-risk disease among older men diagnosed with prostate cancer. METHODS: Records from 1993 to 2014 were reviewed for men who underwent radiotherapy for prostate cancer at age 75 years or older. Patients were classified into one of four groups based on PSA-testing history: (1) no PSA testing; (2) incomplete/ineffective PSA testing; (3) PSA testing; or (4) cannot be determined. Outcomes of interest were National Comprehensive Cancer Network (NCCN) risk group (that is, low, intermediate or high risk) and biopsy grade at diagnosis...
January 3, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27958385/updated-postoperative-nomogram-incorporating-the-number-of-positive-lymph-nodes-to-predict-disease-recurrence-following-radical-prostatectomy
#19
D P Nguyen, M Kent, A Vilaseca, R B Corradi, N Fossati, D D Sjoberg, N Benfante, J A Eastham, P T Scardino, K A Touijer
BACKGROUND: A significant number of patients with minimal lymph node disease at radical prostatectomy (RP) and pelvic lymph node dissection (PLND) have better than expected long-term outcomes. We explored whether stratification by number of positive nodes enhances our institutional prediction model for biochemical recurrence after RP. METHODS: A total of 7789 patients underwent RP and pelvic lymph node dissection from 1995 to 2012 at a tertiary referral center. We compared two recurrence prediction models: one incorporated lymph node invasion and the other tracked the number of positive nodes...
December 13, 2016: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/27922627/blood-based-and-urinary-prostate-cancer-biomarkers-a-review-and-comparison-of-novel-biomarkers-for-detection-and-treatment-decisions
#20
REVIEW
R J Hendriks, I M van Oort, J A Schalken
BACKGROUND: The diagnosis of prostate cancer (PCa) is currently based on serum PSA testing and/or abnormal digital rectal examination and histopathologic evaluation of prostate biopsies. The main drawback of PSA testing is the lack of specificity for PCa. To improve early detection of PCa more specific biomarkers are needed. In the past few years, many new promising biomarkers have been identified; however, to date, only a few have reached clinical practice. METHODS: In this review, we discuss new blood-based and urinary biomarker models that are promising for usage in PCa detection, follow-up and treatment decision-making...
December 6, 2016: Prostate Cancer and Prostatic Diseases
journal
journal
33118
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"